Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials
| العنوان: | Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials |
|---|---|
| المؤلفون: | Angela Dispenzieri, M Hasib Sidiqi, David Dingli, Prashant Kapoor, Francis K. Buadi, Nelson Leung, Martha Q. Lacy, Shaji Kumar, Morie A. Gertz, Robert A. Kyle, Suzanne R. Hayman, Eli Muchtar, Miriam Hobbs, Dragan Jevremovic, Taxiarchis Kourelis, Ronald S. Go, Wilson I. Gonsalves, S. Vincent Rajkumar, Rahma Warsame, Abdullah S. Al Saleh |
| المصدر: | American Journal of Hematology. 96:1131-1136 |
| بيانات النشر: | Wiley, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Antineoplastic Agents, Gastroenterology, Dexamethasone, chemistry.chemical_compound, Refractory, Internal medicine, medicine, Humans, Multiple myeloma, Aged, Aged, 80 and over, Sulfonamides, business.industry, Venetoclax, Hematology, Middle Aged, Bridged Bicyclo Compounds, Heterocyclic, medicine.disease, Lymphoma, Tumor lysis syndrome, Clinical trial, Treatment Outcome, chemistry, Proteasome inhibitor, Female, Multiple Myeloma, business, Follow-Up Studies, medicine.drug |
| الوصف: | Multiple myeloma (MM) remains an incurable disease despite incorporation of novel agents. Venetoclax, a B-cell lymphoma 2 (BCL-2) inhibitor is approved for some hematologic malignancies but not yet for MM, although clinical trials have shown efficacy in patients with MM, particularly those harboring t(11;14). We reviewed the medical records of relapsed and/or refractory MM patients to study the efficacy and safety of venetoclax used outside of clinical trials at Mayo Clinic between December, 2016 and March, 2019. The data cut-off date was August 06, 2020. We identified 56 patients of whom 42 (75%) harbored t(11;14). The median number of prior therapies was six (range 1-15) and 14% of patients had received ≥10 prior lines of therapy. Fifty-three (95%) patients were refractory to an immunomodulatory drug and proteasome inhibitor. Venetoclax was used as monotherapy or doublet, in combination with dexamethasone in 55% (n = 31) and a triplet or quadruplet in 45% of patients. No patient experienced tumor lysis syndrome. Overall response rate in 52 evaluable patients was 44%. The median time to best response was 2 months and median duration of response was 13.6 months. The median PFS for the entire cohort was 5.8 (95% CI 4.9-10.3) months and median OS was 28.4 (95% CI 14.6-not reached) months. The presence of t(11;14) was associated with improved PFS (median 9.7 months vs. 4.2 months, p = 0.019) and OS (median not reached vs. 10.8 9 months, p = 0.015). Venetoclax demonstrates encouraging activity in heavily-treated patients with relapsed/refractory MM, particularly the t(11;14) patient-population. |
| تدمد: | 1096-8652 0361-8609 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a80931d78cbd236d0aab4a4ddd29c3c3 https://doi.org/10.1002/ajh.26269 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi.dedup.....a80931d78cbd236d0aab4a4ddd29c3c3 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 10968652 03618609 |
|---|